Visiongain launches a new pharma report: ‘Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs’ LONDON, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint inhibitors are significant because they utilise the greatest tool that the body has to fight cancer - its own immune defence system. Checkpoint...